Sigmagos – Sigma1 receptor agonists as new therapeutic agents for neuro-degenerative diseases
Sigma receptors have been in the focus of drug discovery
for several years, being classified into two subtypes, sigma-1 and sigma-2 receptors. The sigma-1 receptor is expressed in many different tissue types and is particularly concentrated in certain regions of the central nervous system. Therefore, it represents a new and different avenue in the possible pharmacological treatment of brain related disorders. Several studies have shown that selective agonists of the sigma-1 receptor affect higherordered brain functions such as learning and memory, cognition and mood. These studies indicate that sigma-1 receptor agonists may exert therapeutic effects in dementia, depression, parkinsonism and neuropathic pain. Sigma ligands are also able to modulate endothelial cell proliferation and to control angiogenesis which makes them a promising target for oncology applications. Another area currently being investigated comprises the treatment of immune system disorders.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
First-ever combined heart pump and pig kidney transplant
…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…
Biophysics: Testing how well biomarkers work
LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…